2021 has been a productive year for fungal research. Key studies focused on intestinal inflammation and inflammatory bowel disease highlight antibody-mediated immunity in control of fungal commensalism, commensal and dietary fungi in intestinal inflammation and wound healing, and the therapeutic potential of transgenic yeast engineered to sense and target factors during intestinal inflammation.
Key advances
-
Mycobiota-induced antibodies influence systemic antifungal immunity5 and fungal commensalism in the gut by targeting Candida albicans adhesins6 (Als3) and secreted virulence factors7 (candidalysin and Sap6). Targeting Als3 influenced the severity of colitis in mice6, whereas secretory IgA antibodies to candidalysin and Sap6 are dysregulated in Crohn’s disease7.
-
Food-associated Candida species such as Debaryomyces hansenii can influence intestinal physiology1. D. hansenii found in mouse and human intestinal wounds prevent healing by turning protective macrophages into CCL5-producing perpetuators of tissue recovery1.
-
Transgenic Saccharomyces cerevisiae were engineered to sense and respond to intestinal extracellular ATP and suppress intestinal inflammation in mouse models9, providing a powerful example of mycobiota-centred future therapeutics.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jain, U. et al. Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice. Science 371, 1154–1159 (2021).
Boutin, R. C. T. et al. Bacterial–fungal interactions in the neonatal gut influence asthma outcomes later in life. elife 10, e67740 (2021).
Leonardi, I. et al. CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi. Science 359, 232–236 (2018).
Quinton, J. F. et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42, 788–791 (1998).
Doron, I. et al. Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies. Cell 184, 1017–1031 (2021).
Ost, K. S. et al. Adaptive immunity induces mutualism between commensal eukaryotes. Nature 596, 114–118 (2021).
Doron, I. et al. Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohn’s Disease. Nat. Microbiol. https://doi.org/10.1038/s41564-021-00983-z (2021).
Ruben, S. et al. Ahr1 and Tup1 contribute to the transcriptional control of virulence-associated genes in Candida albicans. mBio 11, e00206-20 (2020).
Scott, B. M. et al. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease. Nat. Med. 27, 1212–1222 (2021).
Break, T. J. et al. Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science 371, eaay5731 (2021).
Acknowledgements
Owing to reference limitations, several seminal and new works could not be cited.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Iliev, I.D. Mycobiota–host immune interactions in IBD: coming out of the shadows. Nat Rev Gastroenterol Hepatol 19, 91–92 (2022). https://doi.org/10.1038/s41575-021-00541-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-021-00541-2
This article is cited by
-
A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease
Indian Journal of Gastroenterology (2024)